沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

开市前 07-03 09:15:31

4.100

+0.000

0.00%

最高4.100	最低4.100	成交量0.00
今开4.100	昨收4.100	日振幅0.00%
总市值27.67亿	流通市值27.67亿	总股本6.75亿
成交额0.00	换手率0.00%	流通股本6.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":4.1,"timestamp":1783040408214,"preClose":4.1,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":675000000,"shares":675000000,"eps":-0.3531243533960784,"marketStatus":"开市前","change":0,"latestTime":"07-03 09:15:31","open":4.1,"high":4.1,"low":4.1,"amount":0,"amplitude":0,"askPrice":4.24,"askSize":1000,"bidPrice":4,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.3531243533960784,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":1,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":4.1,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996","defaultTab":"news","newsList":[{"id":"2648689363","title":"阳普医疗（300030）披露全资子公司完成医疗器械生产许可证变更及延续公告，7月2日股价下跌1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648689363","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648689363?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:12","pubTimestamp":1783005138,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，阳普医疗报收于6.06元，较前一交易日下跌1.3%，最新总市值为18.74亿元。阳普医疗科技股份有限公司于近日披露《关于全资子公司完成医疗器械生产许可证变更及延续的公告》。公告显示，公司全资子公司阳普医疗（湖南）有限公司近日取得湖南省药品监督管理局下发的《医疗器械生产许可证》，完成生产范围变更及许可期限延续。本次变更及延续基于公司业务需要，具体影响尚无法预测。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK0028","BK1574","BK1583","159883","BK0146","BK0251","300030","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648632506","title":"康泰医学（300869）披露医疗器械注册证变更公告，7月2日股价下跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648632506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648632506?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:47","pubTimestamp":1782985641,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，康泰医学报收于10.67元，较前一交易日下跌0.84%，最新总市值为42.87亿元。该股当日开盘10.68元，最高10.95元，最低10.62元，成交额达4689.91万元，换手率为1.65%。康泰医学系统（秦皇岛）股份有限公司于近日收到河北省药品监督管理局通知，公司申请的医疗器械注册证变更事项已获批，并取得《医疗器械注册变更文件》。本次变更有利于优化产品技术参数和性能，提升市场竞争力与临床适配性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200030335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1100","BK0251","300869","159883","09996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648544845","title":"科华生物（002022）披露产品获得医疗器械注册证的公告，7月1日股价上涨3.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648544845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648544845?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:56","pubTimestamp":1782917773,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，科华生物报收于4.74元，较前一交易日上涨3.49%，最新总市值为24.38亿元。该股当日开盘4.57元，最高4.8元，最低4.51元，成交额达3931.56万元，换手率为1.63%。近日，上海科华生物工程股份有限公司及控股子公司苏州天隆生物科技有限公司收到上海市药品监督管理局和国家药品监督管理局颁发的医疗器械注册证。上述产品注册证的取得将丰富公司产品线，对公司业务发展具有正面影响，但公司尚无法预测其对未来营业收入的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1583","BK0046","BK0188","BK1100","BK1574","BK0239","002022","159883","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511193","title":"达安基因（002030）披露取得肺炎衣原体/肺炎支原体核酸检测试剂盒医疗器械注册证，7月1日股价上涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511193","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648511193?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:48","pubTimestamp":1782899306,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，达安基因报收于5.21元，较前一交易日上涨3.37%，最新总市值为73.12亿元。该股当日开盘5.01元，最高5.21元，最低4.97元，成交额达1.22亿元，换手率为1.69%。达安基因于近日取得国家药品监督管理局颁发的医疗器械注册证，产品名称为肺炎衣原体/肺炎支原体核酸检测试剂盒，注册证编号国械注准20263401391，有效期至2031年6月29日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159883","09996","BK0159","BK0046","BK0028","BK1583","002030","BK0122","BK0042","BK1100","BK1574","BK0168","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647055675","title":"创新医疗：上肢主被动运动康复训练系统获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2647055675","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647055675?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:53","pubTimestamp":1782824006,"startTime":"0","endTime":"0","summary":"证券之星消息，创新医疗(002173)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：博灵脑机2026上半年完成二类医疗器械的注册申报工作了吗创新医疗回复：尊敬的投资者，您好。公司控股子公司博灵脑机（杭州）科技有限公司研发的“上肢主被动运动康复训练系统”（即赛博灵科AM5）已于2026年6月26日取得了浙江省药品监督管理局的注册批准，获得医疗器械注册证，具体情况详见2026年6月29日公司披露于巨潮资讯网（www.cninfo.com.cn）的相关公告。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000043978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","BK0077","09996","002173","BK0096","BK0236","BK1574","BK0114","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647360995","title":"键凯科技(688356.SH)拟投资不超3.15亿元用于扩大医疗器械产品生产线等","url":"https://stock-news.laohu8.com/highlight/detail?id=2647360995","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647360995?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:34","pubTimestamp":1782808497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，键凯科技(688356.SH)发布公告，公司拟在天津经济技术开发区投资建设渤海美湾键凯科技健康园区项目(暂定名称)，项目总投资额不超过3.15亿元。该项目规划总建筑面积3.13万平方米，用于扩大医疗器械产品生产线、扩大研发实验室面积、建设健康产业孵化器。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159883","09996","BK1100","BK1583","688356","BK1574","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647500535","title":"国家药监局发布两项“脑机接口”相关医疗器械产品指导原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2647500535","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647500535?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:16","pubTimestamp":1782807403,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","159883","09996","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647202703","title":"透景生命最新公告：全资子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2647202703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647202703?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:51","pubTimestamp":1782726662,"startTime":"0","endTime":"0","summary":"透景生命(300642.SZ)公告称，公司全资子公司江西透景生命科技有限公司近日取得江西省药品监督管理局颁发的1项医疗器械注册证，产品为全自动化学发光免疫分析仪(型号TESMIi60、TESMIi60M)，注册证有效期至2031年6月17日。该注册证将丰富公司化学发光产品线，拓展应用场景，增强体外诊断领域竞争力，但未来业绩影响存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900028167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300642","09996","BK1100","BK1574","159883","BK0046","BK0239","BK1583","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647470763","title":"港股异动 | 沛嘉医疗-B(09996.HK)涨超10% 创新产品放量有望助力公司业绩加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2647470763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647470763?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:23","pubTimestamp":1782703432,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1100","BK1583","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646925314","title":"创新医疗最新公告：控股子公司产品获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2646925314","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646925314?lang=zh_cn&edition=full","pubTime":"2026-06-28 16:01","pubTimestamp":1782633668,"startTime":"0","endTime":"0","summary":"创新医疗(002173.SZ)公告称，公司控股子公司博灵脑机(杭州)科技有限公司研发的“上肢主被动运动康复训练系统”(赛博灵科AM5)于2026年6月26日取得浙江省药品监督管理局颁发的医疗器械注册证。该产品适用于中枢神经损伤导致的上肢功能障碍患者进行康复训练。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800003950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","BK0077","159883","BK0114","BK1583","002173","BK0096","BK1574","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646610315","title":"每周股票复盘：东方生物（688298）获多项国际医疗器械认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2646610315","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646610315?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:23","pubTimestamp":1782588190,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，东方生物报收于17.47元，较上周的19.24元下跌9.2%。本周，东方生物6月24日盘中最高价报19.8元。本周关注点公司公告汇总：杭州丹威生物获中国NMPA三类医疗器械注册证。公司公告汇总浙江东方基因生物制品股份有限公司及下属子公司近期取得多项医疗器械注册证。杭州丹威生物获得中国NMPA三类医疗器械注册证，产品为腺病毒、肺炎支原体和人鼻病毒核酸联合检测试剂盒。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688298","159883","BK1583","09996","BK0239","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365082","title":"东方生物（688298）披露获得多项医疗器械注册证及认证，6月26日股价下跌4.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646365082?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:47","pubTimestamp":1782485236,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，东方生物报收于17.47元，较前一交易日下跌4.27%，最新总市值为35.22亿元。该股当日开盘18.1元，最高18.39元，最低17.44元，成交额达3137.13万元，换手率为0.88%。近日，东方生物披露《关于自愿披露获得医疗器械注册证的公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1574","159883","688298","09996","BK1100","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368265","title":"沛嘉医疗-B(09996.HK)授出233.28万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646368265?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:53","pubTimestamp":1782481988,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","09996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646299368","title":"沛嘉医疗-B(09996)授出233.28万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2646299368","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646299368?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:53","pubTimestamp":1782481988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)发布公告，于2026年6月26日，本公司向若干合资格参与者授出购股权，以供认购本公司合共233.28万股普通股，惟须受限于及遵照本公司于2020年4月28日采纳的购股权计划的条款及条件行事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159891","BK1583","BK1574","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646732178","title":"天益医疗最新公告：新产品取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2646732178","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646732178?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:46","pubTimestamp":1782377192,"startTime":"0","endTime":"0","summary":"天益医疗(301097.SZ)公告称，公司近日收到国家药监局颁发的《医疗器械注册证》，产品为一次性使用连续性肾脏替代治疗管路，适用于连续性肾脏替代治疗(CRRT)时作为血液及液体通道使用。该产品可适配旭化成PlasautoΣ的CRRT设备，丰富了公司血液净化领域产品线，完善了急危重症领域布局，有助于提升核心竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500029942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","09996","BK1574","BK0251","301097","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646847056","title":"天保基建：公司控股子公司天津天保医药科技发展有限公司主要从事医疗器械、中医药药材销售等方面的业务，与创新药无关","url":"https://stock-news.laohu8.com/highlight/detail?id=2646847056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646847056?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:01","pubTimestamp":1782349264,"startTime":"0","endTime":"0","summary":"证券之星消息，天保基建(000965)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：生物医药方面有几大板块？进展怎么样了？自有创新药自研管线进入临床阶段了嘛？联合国资设立生命科学产业基金群，总规模50亿，含8亿AI免疫药物专项基金，对公司园区和生物医药方面产生价值影响了嘛？天保基建回复：您好，公司控股子公司天津天保医药科技发展有限公司主要从事医疗器械、中医药药材销售等方面的业务，与创新药无关。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500007450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000965","06978","09996","BK1515","09939","159992","BK0013","BK0273","BK1161","159883","BK1583","159938","BK0172","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645467832","title":"九强生物（300406）披露取得医疗器械注册证书公告，6月23日股价上涨2.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645467832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645467832?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:24","pubTimestamp":1782224667,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，九强生物报收于11.55元，较前一交易日上涨2.39%，最新总市值为67.72亿元。九强生物于近日披露《关于取得医疗器械注册证书的公告》。公告显示，公司近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品为人ABO血型反定型用红细胞试剂盒，注册证编号为国械注准20263401280，注册类别为Ⅲ类，有效期至2031年6月21日。该产品用于临床检验中的人ABO血型反定型检测，不用于血源筛查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK0046","BK1574","159883","BK0239","BK1100","300406","BK0028","BK0077","BK1583","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645915833","title":"圣湘生物最新公告：肺炎克雷伯菌及KPC基因检测试剂盒获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2645915833","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645915833?lang=zh_cn&edition=full","pubTime":"2026-06-23 19:20","pubTimestamp":1782213602,"startTime":"0","endTime":"0","summary":"圣湘生物(688289.SH)公告称，公司产品肺炎克雷伯菌及耐碳青霉烯类抗生素基因KPC核酸检测试剂盒(荧光PCR法)近日获国家药监局颁发的《医疗器械注册证》，用于体外定性检测人痰液样本中的肺炎克雷伯菌核酸及KPC耐药基因。该产品系公司第二款“病原+耐药”双覆盖产品，进一步完善了呼吸道感染精准诊断领域布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300036573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159883","688289","BK1100","09996","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645688645","title":"九强生物(300406.SZ)取得一项医疗器械注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645688645","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645688645?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:46","pubTimestamp":1782200812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，产品名称：人ABO血型反定型用红细胞试剂盒，该产品用于人ABO血型反定型检测，仅用于临床检验，不用于血源筛查。上述产品医疗器械注册证的取得，丰富了公司在体外诊断血型领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经营将产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300406","BK0012","09996","BK0028","BK1574","159883","BK0239","BK1583","BK0077","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644082805","title":"阳普医疗（300030）披露全资子公司获医疗器械变更注册及延续注册公告，6月18日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644082805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644082805?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:54","pubTimestamp":1781794459,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，阳普医疗报收于6.22元，较前一交易日下跌0.16%，最新总市值为19.23亿元。该股当日开盘6.19元，最高6.33元，最低6.12元，成交额达4000.72万元，换手率为2.36%。阳普医疗于近日披露《关于全资子公司收到医疗器械变更注册（备案）文件及完成延续注册的公告》。涉及产品包括一次性使用防针刺静脉采血针、一次性使用静脉采血针的技术要求变更，以及血栓弹力图仪的延续注册，有效期至2032年5月8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800043052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","300030","BK1583","BK0251","BK1574","BK0028","BK0146","09996","BK1100"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.1314},{"period":"3month","weight":-0.3322},{"period":"6month","weight":-0.3301},{"period":"1year","weight":-0.3862},{"period":"ytd","weight":-0.3178}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.053778},{"month":5,"riseRate":0.6,"avgChangeRate":-0.096849},{"month":6,"riseRate":0.571429,"avgChangeRate":0.041819},{"month":7,"riseRate":0.571429,"avgChangeRate":0.047737},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}